

## CLAIM AMENDMENTS

Claims 1-244 (cancelled)

245. (currently amended) A nucleic acid construct which when present in a cell ~~produces a product~~directs synthesis of a nucleic acid product, said construct ~~having at least one terminus comprising a polynucleotide tail~~comprising a sequence hybridized to a complementary polynucleotide sequence and of a linear polynucleotide tail wherein said polynucleotide tail is covalently attached to an antibody bound to said hybridized polynucleotide sequence, said construct being bound non-ionically to an entity comprising a chemical modification or a ligand.

246. (original) The construct of claim 245 wherein said antibody comprises a polyclonal or monoclonal antibody.

247. (currently amended) A composition comprising:

(a) a non-natural entity which comprises:

(i) at least one domain to a specific nucleic acid component, wherein said domain to said specific nucleic acid component is selected from the group consisting of a linear nucleic acid complementary to a sequence of said specific nucleic acid component and a protein that binds to a ligand of a modified nucleotide in said specific nucleic acid component -and

(ii) at least one domain to a cell of interest, wherein said domain to said cell of interest is selected from the group consisting of a hormone specific to a receptor on said cell of interest, a lectin specific for a sugar on the surface of said cell of interest, a virus particle or viral fragment that binds to a receptor on the surface of said cell of interest and an antibody that recognizes an epitope on the surface of said cell of interest and

(b) said specific nucleic acid component, wherein said nucleic acid component (b) is bound to said non-natural entity (a) through said domain to a

specific nucleic acid component (i), wherein said nucleic acid component is a nucleic acid construct that directs synthesis of a nucleic acid product, wherein said nucleic acid component comprises ~~is a nucleic acid sequence desired to be delivered to said cell of interest~~

~~wherein the domain or domains to said nucleic acid component are different from the domain or domains to said cell, and wherein said specific nucleic acid component is bound to said entity through said domain to a specific nucleic acid component.~~

248. (currently amended) The composition of claim 247, wherein said non-natural entity further comprises a binder.

Claims 249-250 (canceled)

251. (original) The composition of claim 248, wherein said binder is selected from a polymer, a matrix, a support, or a combination of any of the foregoing.

Claim 252 (canceled)

253. (original) The composition of claim 247, wherein said cell is prokaryotic or eukaryotic.

Claims 254-260 (canceled)

261. (original) The composition of claim 247, wherein said cell of interest is contained within an organism.

262. (original) The composition of claim 247, further comprising said cell of interest.

263. (previously presented) A method of introducing a nucleic acid component into a cell comprising:

- (a) providing the composition of claim 247 and
- (b) administering said composition.

264. (original) The method of claim 263, wherein administering is carried out *in vivo*.

265. (original) The method of claim 263, wherein administering is carried out *ex vivo*.

Claims 266-305 (canceled)

306. (new) A kit which comprises:

(a) a non-natural entity which comprises

(i) at least one domain to a specific nucleic acid component, wherein said domain to said specific nucleic acid component is selected from the group consisting of a linear nucleic acid complementary to a sequence of said specific nucleic acid component and a protein that binds to a ligand of a modified nucleotide in said specific nucleic acid component and

(ii) at least one domain to a cell of interest, wherein said domain to said cell of interest is selected from the group consisting of a hormone specific to a receptor on said cell of interest, a lectin specific for a sugar on the surface of said cell of interest, a virus particle or viral fragment that binds to a receptor on the surface of said cell of interest and an antibody that recognizes an epitope on the surface of said cell of interest; and

(b) said specific nucleic acid component and

(c) buffers and instructions,

wherein said specific nucleic acid component (b) is bound to said non-natural entity (a) through said domain to a specific nucleic acid component (i), wherein

said nucleic acid component is a nucleic acid construct that directs synthesis of a nucleic acid product, wherein said nucleic acid component comprises ~~is a nucleic acid sequence desired to be delivered to said cell of interest wherein the domain or domains to said nucleic acid component are different from the domain or domains to said cell, and wherein said specific nucleic acid component is bound to said entity through said domain to a specific nucleic acid component.~~

307. (new) A method of introducing a nucleic acid component into a cell comprising:

- (a) providing the composition of claim 245 and
- (b) administering said composition.